Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.610
-0.030 (-1.83%)
Nov 21, 2024, 12:39 PM EST - Market open

Chemomab Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Selling, General & Admin
3.487.0811.566.031.290.96
Upgrade
Research & Development
12.5518.3816.986.334.685.82
Upgrade
Operating Expenses
16.0325.4628.5312.375.976.78
Upgrade
Operating Income
-16.03-25.46-28.53-12.37-5.97-6.78
Upgrade
Interest Expense
----0.11--0
Upgrade
Interest & Investment Income
0.991.250.96-0.04-
Upgrade
Currency Exchange Gain (Loss)
-0.01-0.01-0.61--0.02-
Upgrade
Pretax Income
-15.05-24.22-28.18-12.48-5.95-6.78
Upgrade
Income Tax Expense
-0.06--0.53---
Upgrade
Net Income
-15-24.22-27.65-12.48-5.95-6.78
Upgrade
Net Income to Common
-15-24.22-27.65-12.48-5.95-6.78
Upgrade
Shares Outstanding (Basic)
131211107-
Upgrade
Shares Outstanding (Diluted)
131211107-
Upgrade
Shares Change (YoY)
19.04%3.26%9.70%51.71%--
Upgrade
EPS (Basic)
-1.12-2.06-2.43-1.20-0.87-
Upgrade
EPS (Diluted)
-1.12-2.06-2.43-1.20-0.87-
Upgrade
Free Cash Flow
-16.13-23.61-20.44-12.61-5.28-6.63
Upgrade
Free Cash Flow Per Share
-1.21-2.01-1.80-1.22-0.77-
Upgrade
EBITDA
-15.97-25.39-28.48-12.33-5.95-6.76
Upgrade
D&A For EBITDA
0.060.070.060.030.020.02
Upgrade
EBIT
-16.03-25.46-28.53-12.37-5.97-6.78
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.